跳转至内容
Merck
CN

G0500

D-(+)-半乳糖胺 盐酸盐

≥99% (HPLC)

别名:

2-氨基-2-脱氧-D-半乳糖 盐酸盐, D-软骨糖胺 盐酸盐

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C6H13NO5 · HCl
化学文摘社编号:
分子量:
215.63
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352201
EC Number:
217-198-1
Beilstein/REAXYS Number:
3697825
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

D-(+)-半乳糖胺 盐酸盐, ≥99% (HPLC)

InChI key

CBOJBBMQJBVCMW-NQZVPSPJSA-N

InChI

1S/C6H13NO5.ClH/c7-3(1-8)5(11)6(12)4(10)2-9;/h1,3-6,9-12H,2,7H2;1H/t3-,4+,5+,6-;/m0./s1

SMILES string

Cl.N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@H](O)CO

assay

≥99% (HPLC)

form

powder

technique(s)

HPLC: suitable

impurities

≤0.5% Glucosamine (HPAE)

color

white to off-white

mp

172-180  °C

solubility

H2O: 50 mg/mL, clear to slightly hazy, colorless to very faintly yellow

storage temp.

room temp

Quality Level

正在寻找类似产品? 访问 产品对比指南

Application

D-(+)-半乳糖盐酸盐已用于:
  • 甘露聚糖结合凝集素(MBL)与改性云母表面的表面结合
  • 腹腔注射前的无菌磷酸盐缓冲液(PBS)中
  • 小鼠中产生原发性骨髓来源的巨噬细胞(BMDM)

D-(+)-半乳糖胺(D-软骨胺)联合脂多糖(LPS)已用于诱导急性肝衰竭模型(LPS/D-GALN诱导肝损伤、肝炎)的治疗研究,以寻找新药。

Biochem/physiol Actions

半乳糖胺(Gal)通过细胞坏死和凋亡诱导肝细胞死亡。它通过产生尿苷二磷酸己糖胺来阻止肝RNA的产生。D-半乳糖胺可降低细胞内尿嘧啶核苷酸库,进而阻止RNA和蛋白质的产生。

General description

D-半乳糖胺(d-GalN)是一种特异性肝毒剂,尤其可在肝细胞内代谢。它是一种源自半乳糖的6碳氨基糖。

Other Notes

为了全面了解我们针对客户研究提供的各种单糖产品,建议您访问我们的碳水化合物分类页面。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Xing Lin et al.
Biological & pharmaceutical bulletin, 37(4), 625-632 (2014-05-13)
This study examined the effect of genistein from Hydrocotyle sibthorpioides on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute hepatic failure. Compared to the model control, genistein treatment significantly protected against LPS/D-GalN-induced liver injury, as evidenced by the decrease in serum alanine and aspartate
Kaicen Wang et al.
mSphere, 5(1) (2020-01-31)
Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on Bifidobacterium longum R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of B. longum R0175 against acute
Aoxiang Zhuge et al.
Applied microbiology and biotechnology, 104(17), 7437-7455 (2020-07-16)
Acute liver failure is a clinical emergency associated with high mortality. Accumulating evidence indicates that gut microbiota participates in the progression of liver injury, and preventive therapies based on altering gut microbiota are of great interest. Previous studies demonstrated that
Yating Li et al.
Applied microbiology and biotechnology, 103(1), 375-393 (2018-10-23)
Acute liver failure is a drastic, unpredictable clinical syndrome with high mortality. Various preventive and adjuvant therapies based on modulating the gut flora have been proposed for hepatic injury. We aimed to explore the preventive and therapeutic effects of Bifidobacterium
Yinhong Zhu et al.
International immunopharmacology, 72, 131-137 (2019-04-14)
Saikosaponin a (SSa), one of the major active components of Bupleurum falcatum, has antioxidant and anti-inflammatory pharmacological properties. However, the effects of SSa on liver injury have not been reported. In the present study, we evaluated the protective effects and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持